The Evaluation of Curative Effect on Treatment of Tumor Above Thalidomide Combined With Megestrol
NCT ID: NCT03777930
Last Updated: 2018-12-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
200 participants
INTERVENTIONAL
2018-12-10
2021-06-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer
NCT06017284
A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT06276933
Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL
NCT07203352
Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC Patients
NCT03489616
PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer
NCT05659186
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
chemotherapy group
the patients were recepted chemotherapy alone
Chemotherapy drugs
According to the NCCN Guidelines
chemotherapy combined with TH and MG group
the patients were recepted chemotherapy combined with thalidomide and megestrol
thalidomide and megestrol acetate
The thalidomide and megestrol acetate administration groups were administered with thalidomide 100 mg qn po and megestrol acetate 0.16 qd po for 8 weeks
the best supportive treatment group
the patients were recepted the best supportive without chemotherapy
optimal support treatment
Patients who cannot tolerate chemotherapy and other cancer treatments receive optimal support for 8 weeks
the best supportive treatment combined with TH and MG group
the patients were recepted the best supportive combined with thalidomide and megestrol without chemotherapy
thalidomide and megestrol acetate
The thalidomide and megestrol acetate administration groups were administered with thalidomide 100 mg qn po and megestrol acetate 0.16 qd po for 8 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Chemotherapy drugs
According to the NCCN Guidelines
thalidomide and megestrol acetate
The thalidomide and megestrol acetate administration groups were administered with thalidomide 100 mg qn po and megestrol acetate 0.16 qd po for 8 weeks
optimal support treatment
Patients who cannot tolerate chemotherapy and other cancer treatments receive optimal support for 8 weeks
thalidomide and megestrol acetate
The thalidomide and megestrol acetate administration groups were administered with thalidomide 100 mg qn po and megestrol acetate 0.16 qd po for 8 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must be able to swallow pills
* The age of the tester ≥ 18 years old
* Gender is not limited
* Kamofsky score \> 20 points
* Estimated survival period ≥ 2 months
* Childbearing age Women need negative pregnancy test
* Patients voluntarily sign informed consent and receive follow-up
* The tester can cooperate to observe adverse events and efficacy
* All of the above conditions can be included
Exclusion Criteria
* 2 or more important organ dysfunction
* Thrombosis Embolism history, except for thrombosis caused by PICC
* Patients suspected of having a history of allergy to thalidomide tablets
* Any significant clinical and laboratory abnormalities that researchers believe affect safety evaluators, such as: uncontrollable activity Microbial infection, grade II or above peripheral neuropathy (NCI CTC AE v4.0), congestive heart failure, myocardial infarction within 6 months, chronic kidney disease, thyroid dysfunction etc, and acceptance may bring significant metabolic or weight changes Patients with clinical disposition
* Patients with mental disorders, affecting the efficacy of the assessor
* During the trial period and within 3 months after the end of the trial, the subject and his partner are not willing to contraception
* Any of the above can not be enrolled.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shenzhen Fifth People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
shenzhenfifth 201807
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.